MedTrace Logo

131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

NCT00293319 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2014-08-18

No results posted yet for this study

Summary

RATIONALE: Radioactive drugs, such as 131 I-MIBG, may carry radiation directly to tumor cells and not harm normal cells.

PURPOSE: This phase II trial is studying how well 131 I-MIBG works in treating patients with refractory or relapsed neuroblastoma.

Conditions

Interventions

BIOLOGICAL

filgrastim

RADIATION

iobenguane I 131

Sponsors & Collaborators

Principal Investigators

  • Katherine K. Matthay, MD · University of California, San Francisco

  • John M. Maris, MD · Children's Hospital of Philadelphia

  • Robert Goldsby, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2006-03-31
Completion
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293319 on ClinicalTrials.gov